Organon & Co.
OGN- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821825
In the last 90 days, Organon & Co. insiders filed 0 open-market purchases and 1 sale; 636 institutions reported holding it in 13F filings for Q2 2026, worth $2.92B in total; no superinvestor holds it.
Holders of 5% or more of OGN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Organon & Co., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 11.90%30.7M shares | – | Apr 30, 20251 filing | Apr 30, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Organon & Co., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 202611:04 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −13.82 ppfrom 13.82%Below 5% | Mar 13, 2026 | SEC |
| Oct 30, 20253:48 PM ET | Vanguard Group Inc | 13G/A | 13.82%35.9M shares | – | Sep 30, 2025 | SEC |
| Apr 30, 202510:12 AM ET | BlackRock, Inc. | 13G/A | 11.90%30.7M shares | – | Mar 31, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Organon & Co. shares.
No Form 144 notices for Organon & Co. are on file.